Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urology | 7 | 2019 | 16 | 2.500 |
Why?
|
| Malpractice | 5 | 2015 | 10 | 1.690 |
Why?
|
| Prostatic Neoplasms | 8 | 2019 | 85 | 1.120 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 155 | 0.860 |
Why?
|
| Clinical Competence | 2 | 2015 | 199 | 0.860 |
Why?
|
| Prostate | 6 | 2019 | 29 | 0.760 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2012 | 26 | 0.690 |
Why?
|
| Kidney Neoplasms | 4 | 2018 | 62 | 0.670 |
Why?
|
| Vena Cava, Inferior | 1 | 2019 | 8 | 0.660 |
Why?
|
| Ureteral Neoplasms | 1 | 2019 | 4 | 0.660 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2018 | 37 | 0.650 |
Why?
|
| SEER Program | 4 | 2013 | 39 | 0.630 |
Why?
|
| Ureteroscopy | 1 | 2018 | 2 | 0.630 |
Why?
|
| Kidney Calculi | 1 | 2018 | 3 | 0.630 |
Why?
|
| Ureteral Calculi | 1 | 2018 | 3 | 0.630 |
Why?
|
| Stents | 1 | 2018 | 64 | 0.600 |
Why?
|
| Simulation Training | 2 | 2019 | 34 | 0.600 |
Why?
|
| Internship and Residency | 2 | 2018 | 196 | 0.580 |
Why?
|
| Models, Educational | 1 | 2017 | 30 | 0.580 |
Why?
|
| Nephrectomy | 3 | 2018 | 28 | 0.540 |
Why?
|
| Image-Guided Biopsy | 3 | 2019 | 30 | 0.460 |
Why?
|
| Prostatectomy | 4 | 2012 | 17 | 0.460 |
Why?
|
| Nephrons | 1 | 2012 | 5 | 0.410 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2012 | 11 | 0.400 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 29 | 0.400 |
Why?
|
| Urologic Diseases | 1 | 2011 | 5 | 0.390 |
Why?
|
| Sarcoidosis | 1 | 2011 | 12 | 0.390 |
Why?
|
| Humans | 25 | 2019 | 25181 | 0.390 |
Why?
|
| Male | 19 | 2019 | 13545 | 0.370 |
Why?
|
| Marital Status | 1 | 2010 | 10 | 0.360 |
Why?
|
| Insurance, Liability | 1 | 2010 | 1 | 0.360 |
Why?
|
| Testicular Neoplasms | 1 | 2010 | 18 | 0.360 |
Why?
|
| Middle Aged | 14 | 2019 | 8136 | 0.350 |
Why?
|
| Penile Neoplasms | 1 | 2008 | 2 | 0.310 |
Why?
|
| Lymph Node Excision | 1 | 2008 | 19 | 0.310 |
Why?
|
| Postoperative Complications | 3 | 2018 | 816 | 0.280 |
Why?
|
| Ultrasonography | 2 | 2019 | 219 | 0.270 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2004 | 92 | 0.270 |
Why?
|
| Liability, Legal | 1 | 2006 | 4 | 0.270 |
Why?
|
| Retrospective Studies | 7 | 2018 | 3105 | 0.270 |
Why?
|
| United States | 5 | 2015 | 1899 | 0.260 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 1113 | 0.260 |
Why?
|
| Biopsy, Needle | 2 | 2005 | 94 | 0.260 |
Why?
|
| Adenocarcinoma | 2 | 2003 | 115 | 0.250 |
Why?
|
| Pneumothorax | 1 | 2005 | 11 | 0.250 |
Why?
|
| Female | 9 | 2019 | 13845 | 0.240 |
Why?
|
| Unnecessary Procedures | 1 | 2005 | 24 | 0.240 |
Why?
|
| Genes, erbB-2 | 1 | 2004 | 6 | 0.230 |
Why?
|
| Aged | 10 | 2018 | 8400 | 0.230 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2004 | 13 | 0.230 |
Why?
|
| Receptor, ErbB-2 | 1 | 2004 | 47 | 0.230 |
Why?
|
| Multivariate Analysis | 4 | 2013 | 278 | 0.220 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2003 | 1 | 0.210 |
Why?
|
| Prostatic Hyperplasia | 1 | 2003 | 8 | 0.210 |
Why?
|
| Genital Neoplasms, Male | 1 | 2002 | 1 | 0.210 |
Why?
|
| Seminal Vesicles | 1 | 2002 | 2 | 0.210 |
Why?
|
| Rectum | 3 | 2018 | 40 | 0.210 |
Why?
|
| Glycoproteins | 1 | 2003 | 46 | 0.210 |
Why?
|
| Neurilemmoma | 1 | 2002 | 14 | 0.210 |
Why?
|
| Proportional Hazards Models | 3 | 2013 | 315 | 0.200 |
Why?
|
| Adult | 6 | 2018 | 7087 | 0.200 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2018 | 46 | 0.190 |
Why?
|
| Time Factors | 2 | 2017 | 1327 | 0.180 |
Why?
|
| Survival Rate | 2 | 2012 | 311 | 0.180 |
Why?
|
| Ultrasonography, Interventional | 2 | 2018 | 59 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 74 | 0.160 |
Why?
|
| Fluoroquinolones | 1 | 2018 | 13 | 0.160 |
Why?
|
| Phantoms, Imaging | 1 | 2018 | 34 | 0.160 |
Why?
|
| Ovariectomy | 1 | 2018 | 22 | 0.160 |
Why?
|
| Hysterectomy | 1 | 2018 | 17 | 0.160 |
Why?
|
| Ureter | 1 | 2018 | 16 | 0.160 |
Why?
|
| Preoperative Period | 1 | 2018 | 73 | 0.150 |
Why?
|
| Treatment Failure | 1 | 2018 | 136 | 0.150 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 72 | 0.150 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 8 | 0.150 |
Why?
|
| Risk Factors | 3 | 2018 | 2167 | 0.140 |
Why?
|
| Renal Veins | 1 | 2017 | 2 | 0.140 |
Why?
|
| Renal Artery | 1 | 2017 | 4 | 0.140 |
Why?
|
| Surgical Stapling | 1 | 2017 | 4 | 0.140 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 30 | 0.140 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 78 | 0.140 |
Why?
|
| Self Report | 1 | 2017 | 199 | 0.130 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 122 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 326 | 0.130 |
Why?
|
| Laparoscopy | 1 | 2017 | 155 | 0.130 |
Why?
|
| Prostate-Specific Antigen | 2 | 2005 | 13 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 1622 | 0.120 |
Why?
|
| Hernia, Inguinal | 1 | 2013 | 16 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 484 | 0.110 |
Why?
|
| Comorbidity | 3 | 2018 | 451 | 0.110 |
Why?
|
| Melanoma | 1 | 2013 | 50 | 0.110 |
Why?
|
| Kidney | 1 | 2013 | 151 | 0.100 |
Why?
|
| Radiotherapy | 1 | 2012 | 31 | 0.100 |
Why?
|
| Genital Diseases, Male | 1 | 2011 | 6 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2012 | 233 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 268 | 0.100 |
Why?
|
| Young Adult | 2 | 2017 | 1749 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2011 | 96 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2010 | 21 | 0.090 |
Why?
|
| Rectal Neoplasms | 1 | 2010 | 11 | 0.090 |
Why?
|
| Prognosis | 2 | 2010 | 727 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 154 | 0.090 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2010 | 28 | 0.090 |
Why?
|
| Incidence | 3 | 2018 | 664 | 0.090 |
Why?
|
| Piperazines | 1 | 2010 | 75 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 175 | 0.080 |
Why?
|
| Physical Examination | 2 | 2005 | 101 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 4503 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 685 | 0.070 |
Why?
|
| Cystectomy | 1 | 2006 | 6 | 0.070 |
Why?
|
| Urination Disorders | 1 | 2005 | 6 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2017 | 3146 | 0.060 |
Why?
|
| Auscultation | 1 | 2005 | 5 | 0.060 |
Why?
|
| Pleura | 1 | 2005 | 9 | 0.060 |
Why?
|
| Respiratory Sounds | 1 | 2005 | 9 | 0.060 |
Why?
|
| Radiography, Thoracic | 1 | 2005 | 22 | 0.060 |
Why?
|
| Case Management | 1 | 2005 | 11 | 0.060 |
Why?
|
| Catheterization, Central Venous | 1 | 2005 | 32 | 0.060 |
Why?
|
| Intraoperative Complications | 1 | 2005 | 60 | 0.060 |
Why?
|
| Biopsy | 2 | 2018 | 191 | 0.060 |
Why?
|
| Gene Amplification | 1 | 2004 | 18 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 29 | 0.060 |
Why?
|
| Urinary Bladder | 1 | 2004 | 19 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 467 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 300 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2003 | 3 | 0.050 |
Why?
|
| Length of Stay | 1 | 2005 | 289 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2003 | 195 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 332 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 1036 | 0.050 |
Why?
|
| Education | 1 | 2019 | 38 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2018 | 30 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 45 | 0.040 |
Why?
|
| Bacterial Infections | 1 | 2018 | 50 | 0.040 |
Why?
|
| Lung | 1 | 2018 | 153 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 294 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2017 | 72 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2018 | 358 | 0.040 |
Why?
|
| Arteriovenous Fistula | 1 | 2017 | 9 | 0.040 |
Why?
|
| Ligation | 1 | 2017 | 31 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2018 | 272 | 0.040 |
Why?
|
| Operative Time | 1 | 2017 | 76 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 277 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 231 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2013 | 592 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2010 | 8 | 0.020 |
Why?
|
| Benzamides | 1 | 2010 | 15 | 0.020 |
Why?
|
| Colectomy | 1 | 2010 | 17 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 57 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 438 | 0.010 |
Why?
|
| Age Factors | 1 | 2005 | 720 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2005 | 1588 | 0.010 |
Why?
|